GPNMB and neoplasm: In this study the observed tumor specific expression of the cell surface marker GPNMB led to the preclinical evaluation of Glembatumumab vedotin (CDX-011), a fully human antibody-drug conjugate (ADC) that targets GPNMB and delivers a cytotoxic dolostatin-like tubulin inhibitor, Monomethyl auristatin E (MMAE) [36, 37].